SCHEMBL5711228

SCHEMBL5711228

CC(C)(C)[Si](C)(C)O[C@@H]1CCC[C@H](O)C1

nearest known ligand 0.38

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
PPM1D O15297 2/20 0.38
CNR2 P34972 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL660447 1.00 PPM1D (0.38) PPM1DCNR2
SCHEMBL9985676 1.00 PPM1D (0.38) PPM1DCNR2
SCHEMBL5711230 1.00 PPM1D (0.38) PPM1DCNR2
SCHEMBL25382185 0.96 PPM1D (0.35) PPM1D
SCHEMBL661089 0.89 PPM1D (0.34) PPM1D
SCHEMBL5831542 0.89 PPM1D (0.34) PPM1D
SCHEMBL20758481 0.89 PPM1D (0.34) PPM1D
SCHEMBL360950 0.89 PPM1D (0.36) PPM1D
SCHEMBL1015667 0.89 PPM1D (0.34) PPM1D
SCHEMBL18535817 0.89 PPM1D (0.34) PPM1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250179027-A1 CYCLOALKYL OR HETEROCYCLYL SUBSTITUTED HETEROARYL COMPOUND, AND COMPOSITION AND USE THEREOF SHENZHEN TARGETRX, INC. (CN) 2025-06-05 US disclosed
EP-4474377-A1 CYCLOALKYL OR HETEROCYCLYL SUBSTITUTED HETEROARYL COMPOUND, AND COMPOSITION AND USE THEREOF Shenzhen TargetRx, Inc. (CN) 2024-12-11 EP disclosed
WO-2023165570-A1 CYCLOALKYL OR HETEROCYCLYL SUBSTITUTED HETEROARYL COMPOUND, AND COMPOSITION AND USE THEREOF 深圳市塔吉瑞生物医药有限公司 2023-09-07 WO disclosed
CN-116693458-A Cycloalkyl or heterocyclyl substituted heteroaryl compounds, compositions and uses thereof 深圳市塔吉瑞生物医药有限公司 2023-09-05 CN disclosed
US-20090312559-A1 CATALYTIC ENANTIOSELECTIVE SILYLATIONS OF SUBSTRATES NATIONAL INSTITUTES OF HEALTH, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT 2009-12-17 US disclosed
EP-1599433-B1 METHOD FOR PRODUCING THE ENANTIOMERIC FORMS OF CIS 1,3-CYCLOHEXANEDIOL DERIVATIVES SANOFI AVENTIS DEUTSCHLAND (DE) 2006-12-06 EP disclosed
US-7094795-B2 Process for preparing the enantiomeric forms of cis-configured 1,3-cyclohexanediol derivatives SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2006-08-22 US disclosed
EP-1599433-A1 METHOD FOR PRODUCING THE ENANTIOMERIC FORMS OF CIS 1,3-CYCLOHEXANEDIOL DERIVATIVES Sanofi-Aventis Deutschland GmbH (DE) 2005-11-30 EP disclosed
US-20040209931-A1 Process for preparing the enantiomeric forms of cis-configured 1,3-cyclohexanediol derivatives AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-10-21 US disclosed
WO-2004076390-A1 METHOD FOR PRODUCING THE ENANTIOMERIC FORMS OF CIS 1,3-CYCLOHEXANEDIOL DERIVATIVES AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-09-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312559-A1 CATALYTIC ENANTIOSELECTIVE SILYLATIONS OF SUBSTRATES LSS, COASY, CYP51A1 PPM1D 4729/4885CNR2 3831/4885
US-20040209931-A1 Process for preparing the enantiomeric forms of cis-configured 1,3-cyclohexanediol derivatives CYP1A1, CYP51A1, CYP1B1 PPM1D 3947/4885CNR2 900/4885
US-20250179027-A1 CYCLOALKYL OR HETEROCYCLYL SUBSTITUTED HETEROARYL COMPOUND, AND COMPOSITION AND USE THEREOF BTK, LYN, SYK PPM1D 206/4885CNR2 1114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.